Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Can-Fite BioPharma is advancing its pancreatic cancer program into a Phase 2b study, evaluating Namodenoson in combination with immunotherapy. The decision follows positive Phase 2a data, which showed a favorable safety profile and clinical activity, including prolonged treatment duration and stable disease in over 30% of evaluable patients. Details of the Phase 2b study design will be discussed at the upcoming BIO International Convention in San Diego, where Can-Fite is meeting with leading oncology companies to explore partnership opportunities.
Key figures
- Drug Name
- Namodenoson
- Phase Of Trial
- Phase 2a, Phase 2b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.